RYSANSO — 2313121
Application number
2313121
Type(s)
Standard Characters
Category
Trademark
CIPO Status
APPROVED
TM5 status
LIVE/APPLICATION/
Under Examination
The trademark application has been accepted by the Office (has met the minimum filing requirements) and that this application has been assigned to an examiner.
Filed
2024-02-29
Applicant
RESILIENT PHARMACEUTICALS, INC.
1 Lincoln St, 31st Floor
Boston, MA 02111
UNITED STATES OF AMERICA
Agent
MINTZ LLP
200 Bay St., South Tower
Suite 2800
Toronto
ONTARIO M5J2J3
Documents
Index headings
- RYSANSO
Goods (Nice class & Statement)
- 5
- (1) Pharmaceutical preparations, namely, psychedelic preparations and psychotropics for the treatment of psychiatric and psychological diseases and disorders, namely PTSD, eating disorders, postpartum depression, alcohol use disorder, opioid and substance use disorder, generalized anxiety disorder, social anxiety disorder, major depressive disorder, and traumatic brain injury; Psychotherapeutic preparations, for managing and treating mental illness and psychiatric, psychological, and neurological disorders and conditions affecting mood, thought, behaviour and perception, namely PTSD, eating disorders, postpartum depression, alcohol use disorder, opioid and substance use disorder, generalized anxiety disorder, social anxiety disorder, major depressive disorder, and traumatic brain injury; Pharmaceutical preparations for the treatment and management of psychiatric, psychological, and neurological disorders, affecting mood, thought, behaviour and perception, namely PTSD, eating disorders, postpartum depression, alcohol use disorder, opioid and substance use disorder, generalized anxiety disorder, social anxiety disorder, major depressive disorder, and traumatic brain injury; Therapeutic agents for treating and managing PTSD, eating disorders, postpartum depression, alcohol use disorder, opioid and substance use disorder, generalized anxiety disorder, social anxiety disorder, major depressive disorder, and traumatic brain injury; Medicaments to help assist with treatment and management of psychiatric, psychological, and neurological disorders, affecting mood, thought, behaviour and perception, namely PTSD, eating disorders, postpartum depression, alcohol use disorder, opioid and substance use disorder, generalized anxiety disorder, social anxiety disorder, major depressive disorder, and traumatic brain injury.
Claims
- Priority Filing Date: August 30, 2023, Country or Office: UNITED STATES OF AMERICA, Application No. 98158134 in association with the same kind of goods
Recordals (known also as Footnotes)
CHANGE IN TITLE / CHANGEMENT EN TITRE: TYPE OF CHANGE / GENRE DE CHANGEMENT: Name / Nom DATE REGISTERED / DATE DE L'ENREGISTREMENT: 2026-02-13 DATE OF CHANGE / DATE DE CHANGEMENT: 2025-07-28 COMMENTS / COMMENTAIRES: FROM/DE: Lykos Therapeutics, Inc. TO/A: RESILIENT PHARMACEUTICALS, INC.Action History
| Action | Action date | Due date | Comments |
|---|---|---|---|
| Filed | 2024-02-29 | ||
| Created | 2024-02-29 | ||
| Formalized | 2024-02-29 | ||
| Pre-Assessment Letter Sent | 2024-03-14 | Retired Goods or Services | |
| Search Recorded | 2025-07-31 | ||
| Examiner's First Report | 2025-07-31 | 2026-01-31 | |
| Amendment to Application | 2026-02-13 | Name/Nom | |
| Approved | 2026-03-26 | APPROVED BY PROGRAM EX200M1 | |
| Approval Notice Sent | 2026-03-26 | APPROVED BY PROGRAM EX200M1 |